CAS 16506-27-7

Bendamustine

Description:

Bendamustine is a synthetic alkylating agent primarily used in the treatment of certain types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. It possesses a unique structure that combines features of both alkylating agents and purine analogs, which contributes to its mechanism of action. Bendamustine functions by interfering with DNA replication and repair, leading to cell cycle arrest and apoptosis in malignant cells. The compound is typically administered intravenously and is known for its relatively favorable side effect profile compared to traditional alkylating agents. Bendamustine is characterized by its moderate solubility in water and its stability under physiological conditions, which allows for effective therapeutic use. Its pharmacokinetics involve rapid distribution and metabolism, with elimination primarily occurring through hepatic pathways. As a result, monitoring liver function is essential during treatment. Overall, Bendamustine represents a valuable option in oncology, particularly for patients who may not respond well to other therapies.

Formula: C₁₆H₂₁Cl₂N₃O₂

InChI: InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)

InChI key: InChIKey=YTKUWDBFDASYHO-UHFFFAOYSA-N

SMILES: CN1C=2C(=CC(N(CCCl)CCCl)=CC2)N=C1CCCC(O)=O

Synonyms:

• 1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-
• 2-Benzimidazolebutyric acid, 5-[bis(2-chloroethyl)amino]-1-methyl-
• 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
• 4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid
• 5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid
• ω-[1-Methyl-5-[bis(β-chloroethyl)amino]-2-benzimidazolyl]butyric acid
• Bendamustine

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

CAS: 16506-27-7

Formula: C₁₆H₂₁Cl₂N₃O₂

Purity: %

Color and Shape: Solid

Molecular weight: 358.2628

Ref: IN-DA007VAS

Bendamustine

CAS: 16506-27-7

Bendamustine

Purity: 98%

Molecular weight: 358.26g/mol

Ref: 54-OR1024330

Bendamustine

CAS: 16506-27-7

Bendamustine

Purity: ≥95%

Molecular weight: 358.26g/mol

Ref: 54-BUP08945

Bendamustine

CAS: 16506-27-7

Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Formula: C₁₆H₂₁Cl₂N₃O₂

Purity: ≥98%

Color and Shape: Solid

Molecular weight: 358.26

Ref: TM-T8380

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

CAS: 16506-27-7

Purity: 98+%

Molecular weight: 358.260009765625

Ref: 10-F436912

Bendamustine

Controlled Product

CAS: 16506-27-7

Applications Bendamustine is an intermediate in the synthesis of Bendamustine 3-Hydroxyprop-2-yl Ester (B132550), which is an impurity of anticancer drug Bendamustine Hydrochloride (B132500).
References Bremer, K., et al.: Tumordiagn. Ther., 17, 1 (1996); Barman Balfour, J.A., et al.: Drugs, 61, 631 (2001);

Formula: C₁₆H₂₁Cl₂N₃O₂

Color and Shape: Neat

Molecular weight: 358.263

Ref: TR-B132558